Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
triopifexor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| tropifexor AM 200 micrograms and Placebo (PM) | EXPERIMENTAL | Tropifexor 200 μg (AM) and Placebo (PM) once daily each |
| tropifexor PM 200 micrograms and Placebo (AM) | EXPERIMENTAL | Tropifexor 200 μg (PM) and Placebo (AM) once daily each |
| Name | Type | Description |
|---|---|---|
| triopifexor | DRUG | Tropifexor as a dry blend in hard gelatin capsules for oral administration |
| Placebo | DRUG | Placebo capsules for oral administration |
Inclusion Criteria: -Presence of Liver Disease Exclusion Criteria: * Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations. * Subjects taking the following medicines UN...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 1 | PHASE1 | BMS-986435 |
| Exelixis, Inc. | EXEL | 1 | PHASE1 | Zanzalintinib |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | Nemtabrutinib |
| Vir Biotechnology, Inc. | VIR | 1 | PHASE1 | VIR-2218, VIR-3434 |
| Pfizer Inc. | PFE | 1 | PHASE1 | PF-07328948 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | SWTX | 1 | PHASE1 | Mirdametinib |
Triopifexor is an investigational small molecule being developed for the treatment of liver disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and tolerability in patients.
Triopifexor is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's safety and tolerability in patients with liver disease.
Triopifexor is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 89 participants with liver disease in the United States. The drug remains investigational and is not yet approved for any use.
Triopifexor has one completed Phase 1 clinical trial registered under NCT04408937, titled 'The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.' The study enrolled 89 participants with liver disease in the United States and was a randomized, double-blind, controlled trial.
Triopifexor is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial focused on evaluating safety and tolerability, and the drug has not yet progressed to later-stage trials or received regulatory approval.